Claims Scope:

Patent issued June 24, 2021. 

≥80% Sequence Identity – Compositions only 

Composition of a viral vector for treating condition associated with the mevalonate pathway, encoding an shRNA or a microRNA that inhibits the mevalonate pathway, comprising shRNA having at least 80% percent identity to SEQ 1-4, or microRNA having at least 80% identity to SEQ 5-10. 

Methods of activating GD T cells and treating cancer.